Cormac Owens

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · Cancers · 2020 · 139 citations · Full text

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

Keith Holmes, Ulrike Pötschger, Andrew D.J. Pearson et al. · Journal of Clinical Oncology · 2020 · 117 citations · Full text

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Jennifer Anderton, V. V. Moroz, Perrine Marec‐Bérard et al. · Trials · 2020 · 105 citations · Full text

Surgical Oncology, Medicine, Cancer Management +5

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial

Bernadette Brennan, Laura Kirton, Perrine Marec‐Bérard et al. · The Lancet · 2022 · 105 citations · Full text

Surgical Oncology, Ewing Sarcoma, Medicine +7